Leaders of the Antibody sector: An interview with Associate Director with Mark Chiu, Janssen Research & Development LLC

Leaders of the Antibody sector: An interview with Associate Director Mark Chiu, Janssen Research and Development LLC

Leaders of the Antibody sector: An interview with Associate Director with Mark Chiu, Janssen Research & Development LLC

Following on from our recent interview with Georg Fey, SpectraMab’s CSO, we’ve also had the pleasure of catching up with Mark Chiu, Associate Director of Janssen Research & Development LLC. Total Biopharma chats with Chiu about the latest challenges and upcoming developments within the Antibody sphere. And while Chiu’s answers are specific and straight-to-the-point, if you want to hear more about the realm of research, developments and challenges that surrounds antibodies, you can hear directly from Chiu and other key members of the speaker faculty at the European Antibody Congress 2014 in Geneva on 10-12 November.

Until then, here’s a couple of the key questions we asked Chiu. Enjoy!

What’s the most exciting project you/your company is working on at the moment in the antibody space?

MC: Being able to engineer manufacturable bispecific antibodies to develop fit for purpose therapeutics.

What do you think is going to be the biggest ‘game changer’ in this sector in the next 18 months – whether it be new product approvals, ground-breaking research or the uptake of new technologies?

MC: Development of bispecific antibodies for chronic indications; validation of bispecific antibody mechanisms of action.

Are there any new technology platforms that you’re watching closely, the implementation of which you think could have a big impact on your work, or the wider antibody space?

MC: The ability to track metabolic pathways to differentiate bispecific Abs from a combination of mAbs.

What do you think is the biggest hurdle to overcome when investigating the CMC and developability of a new molecule?

MC: Understanding the structure function relationships of bispecific Abs and being able to develop the relevant tools to control such relationships.

We’ve recently seen the first approval of a mAb biosimilar in the EU, and there are many more antibody biosimilars in development. What do you think the effect of biosimilar mAb approval in highly regulated markets is going to have on the antibody space?

MC: Biosimilars invite more competition to ensure development of best in class mAbs.

If you could have dinner with any academic, industry or regulatory person working within the antibody space today, to discuss their work and thoughts on this sector – who would it be, and why?

MC: Roy Jefferis to discuss how to better improve the elucidation of the mechanisms of Fc effector function

Specific to the final question there, the opportunity to meet influential academic and industry professionals is clearly key to everyone’s agenda. And so take the opportunity to come face-to-face with global mAb, ADC and next gen technology stakeholders to build invaluable relationships, at the European Antibody Congress 2014. Hope to see you there!

 

European Antibody Congress 2014